Flukes Stephanie, Cohen Marc A, Cunningham Louise M, Wong Richard J, Cracchiolo Jennifer R
Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Speech and Language Pathology, Speech and Hearing Center, Rehabilitation Services, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
J Surg Oncol. 2021 Jan;123(1):149-155. doi: 10.1002/jso.26257. Epub 2020 Oct 15.
Total laryngectomy in thyroid cancer is controversial. Functional and oncologic outcomes are needed to inform surgical indications in this population.
A retrospective cohort study was performed at a tertiary referral center from 1997 to 2018 to identify patients with a diagnosis of thyroid carcinoma who underwent total laryngectomy. Complications, survival outcomes, and functional outcomes were analyzed.
Thirty patients met the inclusion criteria. The mean age was 62 years (range, 30-88 years) and the male-to-female ratio was 1:2.75. The most common diagnosis was well-differentiated thyroid cancer (53.3%), followed by poorly differentiated (30%) and anaplastic (16.7%). Total laryngectomy was performed with a 10% rate of Clavien-Dindo Grade III-V complications. The median overall survival was 40 months (range, 1-237). Five-year overall survival was 39.5% and disease-specific survival was 51.1%. Locoregional control was achieved in 80.0% of patients. Twelve months postoperatively, 100% of surviving patients were taking oral intake and 86.4% had a self-reported functional voice.
Total laryngectomy for locally advanced thyroid cancer is safe and provides acceptable rates of locoregional control. While the risk of distant metastases remains high, advances in systemic therapy may justify aggressive local control strategies to improve the quality of life.
甲状腺癌全喉切除术存在争议。需要功能和肿瘤学结果来指导该人群的手术指征。
在一家三级转诊中心进行了一项回顾性队列研究,研究对象为1997年至2018年期间诊断为甲状腺癌并接受全喉切除术的患者。分析了并发症、生存结果和功能结果。
30例患者符合纳入标准。平均年龄为62岁(范围30 - 88岁),男女比例为1:2.75。最常见的诊断是高分化甲状腺癌(53.3%),其次是低分化癌(30%)和未分化癌(16.7%)。全喉切除术的Clavien-Dindo III - V级并发症发生率为10%。中位总生存期为40个月(范围1 - 237个月)。5年总生存率为39.5%,疾病特异性生存率为51.1%。80.0%的患者实现了局部区域控制。术后12个月,100%的存活患者经口进食,86.4%的患者自我报告有功能性嗓音。
局部晚期甲状腺癌的全喉切除术是安全的,且能提供可接受的局部区域控制率。虽然远处转移风险仍然很高,但全身治疗的进展可能证明积极的局部控制策略对改善生活质量是合理的。